Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349278 | 0.95 | THRB (0.42) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14339753 | 0.92 | THRB (0.47) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL14339757 | 0.91 | LMNA (0.44) | LMNAALDH1A1THRBHDAC6HDAC8 | |
| SCHEMBL14339573 | 0.90 | LMNA (0.45) | LMNAKDM4ETHRBHDAC6HDAC8 | |
| SCHEMBL14339752 | 0.89 | THRB (0.49) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5358434 | 0.88 | LMNA (0.41) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5356883 | 0.88 | LMNA (0.40) | LMNAALDH1A1THRBHDAC6HDAC8 | |
| SCHEMBL5353958 | 0.88 | RXFP1 (0.44) | LMNAHDAC6HDAC8RXFP1 | |
| SCHEMBL5356010 | 0.88 | LMNA (0.46) | LMNATHRBTOP1RXFP1 | |
| SCHEMBL5353229 | 0.87 | LMNA (0.40) | LMNATHRBHDAC6HDAC8TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | LMNA 4460/4885KDM4E 3960/4885ALDH1A1 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.